Trial Profile
Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Cladribine; Filgrastim; Pegfilgrastim; Rituximab
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Jan 2018 Status changed from active, no longer recruiting to completed.
- 18 Jun 2012 Planned End Date changed from 1 Dec 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
- 19 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.